	US 12,202,904 B2
	IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells
Harvey Cantor, Boston, MA (US); Hye-Jung Kim, Brookline, MA (US); and Jessica M. Sido, Ayer, MA (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed on Feb. 27, 2023, as Appl. No. 18/114,832.
Application 18/114,832 is a continuation of application No. 16/609,918, granted, now 11,591,403, previously published as PCT/US2018/030636, filed on May 2, 2018.
Claims priority of provisional application 62/500,443, filed on May 2, 2017.
Prior Publication US 2023/0406944 A1, Dec. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); G01N 33/50 (2006.01)

CPC C07K 16/2866 (2013.01) [A61K 39/3955 (2013.01); A61K 39/4611 (2023.05); A61K 39/4621 (2023.05); A61K 39/464419 (2023.05); A61K 39/464438 (2023.05); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12N 5/0637 (2013.01); G01N 33/505 (2013.01); A61K 2039/505 (2013.01); A61K 2239/50 (2023.05); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/92 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/998 (2013.01); C12N 2506/11 (2013.01)]

4 Claims

1. A method for inducing differentiation of a regulatory T (Treg) cell to an effector T (Teff) cell, comprising contacting the Treg cell with an agent that decreases IL-23R activity and does not decrease IL-12Rβ activity;

wherein the agent comprises a human or humanized antibody derived from mouse monoclonal antibody 12B2B64.